Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Issue 1

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Authors Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Published Date May 2011 Volume 2011:7(1) Pages 303—312

DOI http://dx.doi.org/10.2147/NDT.S18333

Published 24 May 2011

Robert M Berman1, Michael E Thase2, Madhukar H Trivedi3, James A Hazel4, Sabrina Vogel Marler5, Robert D McQuade6, William Carson7, Ross A Baker8, Ronald N Marcus9
1Neuroscience Global Clinical Research Bristol-Myers Squibb, Wallingford, CT, USA; 2Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA; 3Division of Mood Disorders Research Program and Clinic, University of Texas Southwestern Medical School, Dallas, TX, USA; 4Neuroscience Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT, USA; 5Global Biometric Sciences, Bristol-Myers Squibb, Wallingford, CT, USA; 6Global Medical Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 7Global Clinical Development, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, NJ, USA; 8Neuroscience Medical Strategy, Bristol-Myers Squibb Company, Plainsboro, NJ, USA; 9Neuroscience Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT, USA

Background: Effective management of major depressive disorder often includes the long-term use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole has not been evaluated in a controlled setting.
Patients and methods: Patients (n = 706) completing one of two 14-week double-blind studies of aripiprazole augmentation, as well as de novo patients (n = 296) nonresponsive to current antidepressant therapy, were enrolled in this open-label study. Patients received open-label aripiprazole for up to 52 weeks.
Results: Open-label treatment was completed by 323 patients (32.2%). At endpoint (n = 987), the mean dose of aripiprazole was 10.1 mg/day. Common (>15% of patients) spontaneously reported adverse events were akathisia (26.2%), fatigue (18.0%), and weight gain (17.1%). The incidence of serious adverse events was 4.0%. Four spontaneous reports of possible tardive dyskinesia were submitted (0.4%); all resolved within 45 days of drug discontinuation. Mean weight change was 4.4 kg; 36.6% experienced ≥7% increase in weight from baseline (observed case analysis, n = 303). No clinically relevant changes in other metabolic parameters were seen. At the end of open-label treatment, 221 patients (69.7%) had a Clinical Global Impression-Severity of Illness score of 1 (not at all ill) or 2 (borderline ill).
Conclusion: Long-term adjunctive aripiprazole therapy was well tolerated with an acceptable long-term safety and tolerability profile in patients with major depressive disorder who had not responded to treatment with one or more antidepressant therapies. Clinically significant weight gain was observed in about one-third of patients. Overall, the adverse event profile was consistent with that reported in the short-term trials and readily managed clinically.

Keywords: adjunctive aripiprazole, antidepressant therapy, major depressive disorder, long-term safety and tolerability

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Augmentation treatment in major depressive disorder: focus on aripiprazole

J Craig Nelson, Andrei Pikalov, Robert M Berman

Neuropsychiatric Disease and Treatment 2008, 4:937-948

Published Date: 11 August 2008

Readers of this article also read:

Augmentation treatment in major depressive disorder: focus on aripiprazole

J Craig Nelson, Andrei Pikalov, Robert M Berman

Neuropsychiatric Disease and Treatment 2008, 4:937-948

Published Date: 11 August 2008

Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease

Roy C Orlando, Sherry Liu, Marta Illueca

Clinical and Experimental Gastroenterology 2010, 3:117-125

Published Date: 6 September 2010

Psychiatric disorders in primary focal dystonia and in Parkinson’s disease

Fernando MV Dias, Arthur Kummer, Flávia CP Doyle, et al

Neuropsychiatric Disease and Treatment 2011, 7:111-116

Published Date: 14 March 2011

Olmesartan/amlodipine: a review of its use in the management of hypertension

Kreutz R

Vascular Health and Risk Management 2011, 7:183-192

Published Date: 29 March 2011

The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder

Pompili M, Venturini P, Innamorati M , Serafini G, Telesforo L, Lester D, Tatarelli R, Girardi P

Neuropsychiatric Disease and Treatment 2011, 7:259-265

Published Date: 6 May 2011

Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence

McIntyre R, Yoon J, Jerrell JM, Liauw SS

Neuropsychiatric Disease and Treatment 2011, 7:319-323

Published Date: 25 May 2011

Role of sublingual asenapine in treatment of schizophrenia

Citrome L

Neuropsychiatric Disease and Treatment 2011, 7:325-339

Published Date: 26 May 2011

The management of schizophrenia: focus on extended-release quetiapine fumarate

Peuskens J

Neuropsychiatric Disease and Treatment 2011, 7:549-564

Published Date: 21 September 2011